ANIX

Announcements

Nothing here yet

Daily updates

• Anixa Biosciences dosed the second patient in the highest-dose cohort of its Phase 1 FSHR-directed CAR-T trial for recurrent ovarian cancer, with no dose-limiting toxicities reported to date. Early signals showed four heavily pretreated patients surviving beyond one year after infusion, including one surviving more than two years, as dose escalation continues.Oct 4, 2026

FDA designations

Nothing here yet

News

• Anixa Biosciences receives its first Australian patent for its breast cancer vaccine, extending global protection through 2040Sep 21, 2026
• Anixa Biosciences expanded its global patent portfolio with Australian patent acceptance for its breast cancer vaccine technologyJul 14, 2026
• Anixa Biosciences and Moffitt Cancer Center advanced their ovarian cancer CAR-T trial to the highest dose level testedJul 8, 2026
• Anixa Biosciences received its first Korean patent for its breast cancer vaccineJul 1, 2026
• Anixa Biosciences reports updated positive survival data from Phase 1 ovarian cancer CAR-T trialMay 12, 2026